Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

GOSSGossamer Bio, Inc.

Nasdaq · CIK 0001728117
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts304

Identity from submissions API

NameGossamer Bio, Inc.
CIK0001728117
TickersGOSS
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN475461709
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(858) 684-1300
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
3115 MERRYFIELD ROW
SUITE 120
SAN DIEGO
CA
92121
CA
Mailing address
3115 MERRYFIELD ROW
SUITE 120
SAN DIEGO
CA
92121
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

490 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 S-3 S-3 0001728117-26-000123 333-300084 261561639 33 520979 1 1
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-128345 005-91334 261561335 34 17145
2026-11-10 8-K 8-K 2.02,9.01 0001728117-26-000116 001-38796 261541252 34 249679 1 1
2026-11-10 10-Q 10-Q 0001728117-26-000114 001-38796 261541237 34 8464919 1 1
2026-11-06 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001493152-26-050449 005-91334 261531854 34 23809
2026-11-06 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-002941 005-91334 261529765 34 11471
2026-10-29 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001104659-26-120319 005-91334 261503612 34 67443
2026-10-28 8-K 8-K 5.07 0001728117-26-000109 001-38796 261495673 34 145304 1 1
2026-10-08 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001104659-26-114792 005-91334 261450973 34 54837
2026-09-28 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001104659-26-111463 005-91334 261418734 34 87977
2026-09-28 8-K 8-K 8.01 0001728117-26-000106 001-38796 261417180 34 138624 1 1
2026-09-25 4 FORM 4 0001628280-26-063624 5510
2026-09-25 4 FORM 4 0001628280-26-063619 5530
2026-09-25 4 FORM 4 0001628280-26-063616 5465
2026-09-25 4 FORM 4 0001628280-26-063610 5518
2026-09-25 4 FORM 4 0001628280-26-063606 5481
2026-09-25 4 FORM 4 0001628280-26-063601 5528
2026-09-25 4 FORM 4 0001628280-26-063593 5526
2026-09-23 8-K 8-K 8.01 0001728117-26-000104 001-38796 261401088 34 145460 1 1
2026-09-22 3 FORM 3 0001628280-26-063097 506430
2026-09-16 DEF 14A DEF 14A 0001728117-26-000102 001-38796 261384140 34 4851558 1 1
2026-09-16 8-K 8-K 5.02,9.01 0001728117-26-000101 001-38796 261383788 34 165102 1 1
2026-09-11 8-K 8-K 3.03,5.03,8.01,9.01 0001728117-26-000094 001-38796 261372718 34 194782 1 1
2026-09-09 8-K 8-K 8.01,9.01 0001728117-26-000091 001-38796 261366878 34 174118 1 1
2026-09-04 D xslFormDX01/primary_doc.xml 06b 0001728117-26-000088 021-596541 261362657 33 15677
2026-09-03 PRE 14A PRE 14A 0001728117-26-000086 001-38796 261358288 34 4762621 1 1
2026-09-03 8-K 8-K 5.03,9.01 0001728117-26-000085 001-38796 261358247 34 443262 1 1
2026-08-26 4 FORM 4 0001553179-26-000005 6135
2026-08-26 4 FORM 4 0001857256-26-000006 6095
2026-08-26 4 FORM 4 0002003059-26-000008 6150
2026-08-26 4 FORM 4 0001740847-26-000006 9345
2026-08-26 4 FORM 4 0001352620-26-000006 9394
2026-08-26 8-K 8-K 5.03,9.01 0001728117-26-000079 001-38796 261322556 34 265788 1 1
2026-08-24 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001104659-26-100440 005-91334 261312120 34 92654
2026-08-21 8-K 8-K 1.01,3.02,5.03,7.01,9.01 0001728117-26-000077 001-38796 261301750 34 1546877 1 1
2026-08-13 8-K 8-K 2.02,9.01 0001728117-26-000073 001-38796 261273048 34 254281 1 1
2026-08-13 10-Q 10-Q 0001728117-26-000072 001-38796 261273032 34 8069019 1 1
2026-07-29 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001493152-26-035186 005-91334 261217357 34 22953
2026-07-29 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-002802 005-91334 261216900 34 10760
2026-07-27 8-K 8-K 1.01,1.02,2.02,7.01,8.01,9.01 0001728117-26-000064 001-38796 261205658 34 442041 1 1
2026-07-24 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001104659-26-086735 005-91334 261202681 34 70826
2026-07-15 8-K 8-K 5.02,5.03,5.07,9.01 0001728117-26-000061 001-38796 261175655 34 7655114 1 1
2026-07-01 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001104659-26-080004 005-91334 261147518 34 64789
2026-07-01 8-K 8-K 7.01,9.01 0001728117-26-000057 001-38796 261142890 34 156207 1 1
2026-06-17 8-K 8-K 7.01,9.01 0001728117-26-000054 001-38796 261096634 34 173271 1 1
2026-06-11 SCHEDULE 13D xslSCHEDULE_13D_X02/primary_doc.xml 0001104659-26-073089 005-91334 261084764 34 72752
2026-06-11 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-073064 005-91334 261084653 34 25827
2026-06-11 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001404574-26-000021 005-91334 261083898 34 12645
2026-06-09 DEF 14A DEF 14A 0001728117-26-000052 001-38796 261076337 34 4292543 1 1
2026-06-09 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001301396-26-000003 005-91334 261074705 34 620028
2026-06-05 4 FORM 4 0001728117-26-000047 5726
2026-06-05 4 FORM 4 0002015102-26-000001 5763
2026-06-05 4 FORM 4 0001538894-26-000002 5775
2026-06-05 4 FORM 4 0001512984-26-000001 5773
2026-06-05 4 FORM 4 0001859810-26-000003 5755
2026-06-05 4 FORM 4 0002015114-26-000001 5771
2026-06-05 8-K 8-K 1.01,1.02,2.03,3.02,7.01,9.01 0001728117-26-000045 001-38796 261066535 34 128990604 1 1
2026-06-05 8-K 8-K 5.07 0001728117-26-000042 001-38796 261066141 34 156439 1 1
2026-06-02 8-K 8-K 8.01,9.01 0001728117-26-000040 001-38796 261053656 34 174001 1 1
2026-05-18 PRE 14A PRE 14A 0001728117-26-000038 001-38796 26990765 34 4275485 1 1
2026-05-18 DEFA14A DEFA14A 0001728117-26-000037 001-38796 26990764 34 552851
2026-05-18 8-K 8-K 1.01,2.02,5.02,7.01,8.01 0001728117-26-000036 001-38796 26990763 34 774752 1 1
2026-05-15 10-Q 10-Q 0001728117-26-000032 001-38796 26986705 34 6111009 1 1
2026-05-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001214659-26-006204 005-91334 26978573 34 11744
2026-04-24 ARS ARS 0001728117-26-000029 001-38796 26893499 34 29177621
2026-04-24 DEFA14A DEFA14A 0001728117-26-000028 001-38796 26893468 34 283034
2026-04-24 DEF 14A DEF 14A 0001728117-26-000027 001-38796 26893450 34 3554986 1 1
2026-04-09 8-K 8-K 3.01 0001728117-26-000022 001-38796 26851519 34 144992 1 1
2026-03-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-001439 005-91334 26801487 34 7163
2026-03-24 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001085146-26-000283 005-91334 26787077 34 10744
2026-03-20 4 FORM 4 0001867872-26-000004 53380
2026-03-20 4 FORM 4 0001857256-26-000004 53382
2026-03-20 4 FORM 4 0002003059-26-000006 12438
2026-03-20 4 FORM 4 0001352620-26-000004 45250
2026-03-20 4 FORM 4 0001740847-26-000004 49326
2026-03-20 4 FORM 4 0001553179-26-000004 45233
2026-03-18 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-000860 333-293009 26772218 33 1760
2026-03-17 POS AM POS AM 0001728117-26-000020 333-293009 26761932 33 299913
2026-03-17 8-K 8-K 2.02,9.01 0001728117-26-000018 001-38796 26761714 34 244502 1 1
2026-03-17 10-K 10-K 0001728117-26-000017 001-38796 26761678 34 10020082 1 1
2026-03-17 POSASR POSASR 0001728117-26-000016 333-293009 26761650 33 584548 1 1
2026-03-02 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001404574-26-000006 005-91334 26705393 34 11000
2026-02-24 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001072613-26-000213 005-91334 26673661 34 89598
2026-02-23 8-K 8-K 8.01 0001728117-26-000004 001-38796 26662178 34 3489951 1 1
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-26-002007 005-91334 26640727 34 11598
2026-01-28 S-3ASR S-3ASR 0001728117-26-000002 333-293009 26572412 33 990910 1 1
2026-01-21 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-26-000670 005-91334 26545827 34 10830
2026-01-05 4 FORM 4 0001352620-26-000002 7868
2026-01-05 4 FORM 4 0001740847-26-000002 7818
2026-01-05 4 FORM 4 0002003059-26-000003 7883
2026-01-05 4 FORM 4 0001867872-26-000002 7823
2026-01-05 4 FORM 4 0001857256-26-000002 7134
2026-01-05 4 FORM 4 0001553179-26-000002 8561
2025-11-05 8-K 8-K 2.02,9.01 0001728117-25-000082 001-38796 251455218 34 244584 1 1
2025-11-05 10-Q 10-Q 0001728117-25-000081 001-38796 251455212 34 6881036 1 1
2025-10-02 4 FORM 4 0002003059-25-000004 5624
2025-10-02 4 FORM 4 0001553179-25-000004 6302
2025-10-02 4 FORM 4 0001740847-25-000003 5558
2025-10-02 4 FORM 4 0001867872-25-000003 5564
2025-10-02 4 FORM 4 0001352620-25-000004 5605
2025-10-02 4 FORM 4 0001857256-25-000004 4875
2025-09-25 8-K 8-K 3.02 0001728117-25-000076 001-38796 251340364 34 147302 1 1
2025-08-20 4 FORM 4 0001728117-25-000072 4432
2025-08-05 8-K 8-K 2.02,9.01 0001728117-25-000069 001-38796 251184774 34 249453 1 1
2025-08-05 10-Q 10-Q 0001728117-25-000068 001-38796 251184759 34 6749675 1 1
2025-07-29 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000900 005-91334 251159998 34 6170
2025-07-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-003058 005-91334 251132227 34 10692
2025-06-26 4 FORM 4 0001728117-25-000061 5623
2025-06-26 4 FORM 4 0001728117-25-000059 5631
2025-06-26 4 FORM 4 0001728117-25-000057 5650
2025-06-26 4 FORM 4 0001728117-25-000055 5586
2025-06-26 4 FORM 4 0001728117-25-000053 5598
2025-06-26 4 FORM 4 0001728117-25-000051 5623
2025-06-25 8-K 8-K 5.02,5.07 0001728117-25-000043 001-38796 251073587 34 165029 1 1
2025-06-16 8-K 8-K 7.01,8.01,9.01 0001728117-25-000040 001-38796 251048535 34 184817 1 1
2025-05-15 8-K 8-K 2.02,9.01 0001728117-25-000037 001-38796 25952450 34 242392 1 1
2025-05-15 10-Q 10-Q 0001728117-25-000036 001-38796 25952393 34 5757569 1 1
2025-04-29 ARS ARS 0001728117-25-000031 001-38796 25887007 34 17700794
2025-04-29 DEFA14A DEFA14A 0001728117-25-000030 001-38796 25886989 34 272705
2025-04-29 DEF 14A DEF 14A 0001728117-25-000029 001-38796 25886974 34 3851486 1 1
2025-03-13 S-8 S-8 0001728117-25-000023 333-285779 25735659 33 191534
2025-03-13 8-K 8-K 2.02,9.01 0001728117-25-000022 001-38796 25735642 34 238796 1 1
2025-03-13 10-K 10-K 0001728117-25-000021 001-38796 25735631 34 10678447 1 1
2025-03-06 4 FORM 4 0001728117-25-000017 5461
2025-03-06 4 FORM 4 0001728117-25-000015 5502
2025-03-06 4 FORM 4 0001728117-25-000013 5510
2025-03-06 4 FORM 4 0001728117-25-000012 5459
2025-03-06 4 FORM 4 0001728117-25-000010 5451
2025-03-06 4 FORM 4 0001728117-25-000008 5457
2025-02-19 8-K 8-K 8.01 0001728117-25-000004 001-38796 25639771 34 150729 1 1
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-018890 005-91334 25615268 34 18757
2025-02-05 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-002037 005-91334 25594858 34 10944
2025-01-30 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000166 005-91334 25575643 34 6315
2024-11-12 SC 13G/A SC 13G/A 0001193125-24-256038 005-91334 241449173 34 146667
2024-11-12 SC 13G/A filing.txt 0000315066-24-002720 005-91334 241444512 34 8146
2024-11-07 8-K 8-K 2.02,9.01 0001728117-24-000093 001-38796 241435411 34 440821 1 1
2024-11-07 10-Q 10-Q 0001728117-24-000092 001-38796 241435386 34 6747565 1 1
2024-09-13 8-K 8-K 3.01 0001728117-24-000088 001-38796 241297654 34 154074 1 1
2024-08-12 8-K 8-K 2.02,9.01 0001728117-24-000086 001-38796 241196658 34 450154 1 1
2024-08-12 10-Q 10-Q 0001728117-24-000085 001-38796 241196642 34 7832492 1 1
2024-08-02 SC 13G/A SC 13G/A 0001193125-24-193046 005-91334 241172621 34 191692
2024-07-18 8-K 8-K 8.01 0001728117-24-000080 001-38796 241124767 34 150825 1 1
2024-06-25 4 FORM 4 0001728117-24-000078 5353
2024-06-24 4 FORM 4 0001728117-24-000076 6031
2024-06-20 4 FORM 4 0001728117-24-000073 5095
2024-06-20 4 FORM 4 0001728117-24-000072 4598
2024-06-10 8-K 8-K 5.07 0001728117-24-000069 001-38796 241032600 34 165793 1 1
2024-06-06 4 FORM 4 0001728117-24-000067 5549
2024-06-06 4 FORM 4 0001728117-24-000066 5561
2024-06-06 4 FORM 4 0001728117-24-000065 5613
2024-06-06 4 FORM 4 0001728117-24-000064 5586
2024-05-24 8-K 8-K 3.01 0001728117-24-000059 001-38796 24984918 34 154034 1 1
2024-05-07 8-K 8-K 2.02,9.01 0001728117-24-000057 001-38796 24921674 34 430190 1 1
2024-05-07 10-Q 10-Q 0001728117-24-000056 001-38796 24921659 34 5625485 1 1
2024-05-06 8-K 8-K 1.01,1.02,3.02,8.01,9.01 0001728117-24-000052 001-38796 24915583 34 409372 1 1
2024-04-26 ARS ARS 0001728117-24-000050 001-38796 24882100 34 16244740
2024-04-24 DEFA14A DEFA14A 0001728117-24-000045 001-38796 24870506 34 197508
2024-04-24 DEF 14A DEF 14A 0001728117-24-000044 001-38796 24870494 34 3374669 1 1
2024-03-28 4 FORM 4 0001728117-24-000041 6486
2024-03-28 4 FORM 4 0001728117-24-000039 5741
2024-03-28 4 FORM 4 0001728117-24-000037 5748
2024-03-19 4 FORM 4 0001728117-24-000034 5056
2024-03-19 4 FORM 4 0001728117-24-000033 5057
2024-03-12 4 FORM 4 0001728117-24-000031 5332
2024-03-12 4 FORM 4 0001728117-24-000029 5302
2024-03-12 3 FORM 3 0001728117-24-000027 6373
2024-03-12 3 FORM 3 0001728117-24-000026 6385
2024-03-12 8-K 8-K 5.02,9.01 0001728117-24-000024 001-38796 24741977 34 197003 1 1
2024-03-05 S-8 S-8 0001728117-24-000020 333-277653 24718297 33 189776
2024-03-05 10-K 10-K 0001728117-24-000019 001-38796 24718289 34 9725237 1 1
2024-03-05 8-K 8-K 2.02,9.01 0001728117-24-000018 001-38796 24718286 34 224243 1 1
2024-03-04 8-K 8-K 8.01 0001728117-24-000013 001-38796 24714925 34 152783 1 1
2024-02-14 SC 13G/A GOSSAMER BIO, INC. 0000902664-24-001739 005-91334 24639497 34 46058
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-021039 005-91334 24628566 34 12983
2024-02-09 SC 13G/A ARCH VENTURE FUND IX, L.P. - GOSSAMER BIO -- SCH 13G/A(#1-EXIT) 0001072613-24-000116 005-91334 24616362 34 83587
2024-02-09 SC 13G filing.txt 0000315066-24-001145 005-91334 24611633 34 8098
2024-01-11 SC 13G SC 13G 0001193125-24-006630 005-91334 24529579 34 170146
2024-01-11 SC 13G/A GOSS_SC13GA1.htm 0001273087-24-000008 005-91334 24529350 34 81545
2024-01-04 4 FORM 4 0001728117-24-000010 5413
2024-01-04 4 FORM 4 0001728117-24-000008 5454
2024-01-04 4 FORM 4 0001728117-24-000006 5411
2024-01-04 4 FORM 4 0001728117-24-000004 5403
2024-01-04 4 FORM 4 0001728117-24-000002 5409
2023-12-05 4 FORM 4 0001728117-23-000164 5386
2023-12-05 3 FORM 3 0001728117-23-000163 6397
2023-11-29 4 FORM 4 0001728117-23-000160 5177
2023-11-29 3 FORM 3 0001728117-23-000158 6259
2023-11-29 8-K 8-K 5.02,9.01 0001728117-23-000157 001-38796 231452104 34 191948 1 1
2023-11-27 8-K 8-K 5.02,5.03,9.01 0001728117-23-000151 001-38796 231440281 34 692117 1 1
2023-11-22 4 FORM 4 0001728117-23-000148 5333
2023-11-22 4 FORM 4 0001728117-23-000147 5325
2023-11-22 4 FORM 4 0001728117-23-000146 5335
2023-11-22 4 FORM 4 0001728117-23-000145 5328
2023-11-22 4 FORM 4 0001728117-23-000144 5376
2023-11-17 4 FORM 4 0001728117-23-000138 4408
2023-11-14 4 FORM 4 0001728117-23-000136 5430
2023-11-09 10-Q 10-Q 0001728117-23-000134 001-38796 231390080 34 5880424 1 1
2023-11-09 8-K 8-K 2.02,9.01 0001728117-23-000133 001-38796 231390079 34 432776 1 1
2023-10-20 8-K 8-K 3.01 0001728117-23-000129 001-38796 231337151 34 157162 1 1
2023-09-07 8-K 8-K 5.02 0001728117-23-000127 001-38796 231242956 34 153310 1 1
2023-08-28 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-08-28 16:00:00 9999999995-23-002516 333-274056 231217933 33 1656
2023-08-28 424B3 424B3 0001728117-23-000124 333-274056 231216146 33 283827
2023-08-24 UPLOAD filename1.pdf 0000000000-23-009357 40100
2023-08-24 CORRESP filename1.htm 0001728117-23-000121 7351
2023-08-21 DEL AM DEL AM 0001728117-23-000118 333-274056 231189089 33 7785
2023-08-18 S-3 S-3 0001728117-23-000116 333-274056 231183830 33 475247
2023-08-18 RW RW 0001728117-23-000114 333-274045 231183828 NE 6873
2023-08-17 S-3ASR S-3ASR 0001728117-23-000112 333-274045 231181814 33 477438
2023-08-08 10-Q 10-Q 0001728117-23-000108 001-38796 231151120 34 5951278 1 1
2023-08-08 8-K 8-K 2.02,9.01 0001728117-23-000107 001-38796 231151070 34 431494 1 1
2023-08-07 D xslFormDX01/primary_doc.xml 06b 0001567619-23-006809 021-488995 231148172 33 15844
2023-07-28 SC 13D GROWTH EQUITY OPPORTUNITIES 18 VGE, LLC / GOSSAMER BIO, INC. -- SCHEDULE 13D 0001072613-23-000402 005-91334 231122852 34 445582
2023-07-26 4 FORM 4 0001728117-23-000100 7216
2023-07-26 4 FORM 4 0001728117-23-000099 7225
2023-07-26 4 FORM 4 0001728117-23-000098 7957
2023-07-20 8-K 8-K 1.01,3.02,7.01,9.01 0001728117-23-000094 001-38796 231099719 34 732354 1 1
2023-07-20 8-K 8-K 8.01,9.01 0001728117-23-000091 001-38796 231098099 34 5067962 1 1
2023-06-26 4 FORM 4 0001728117-23-000086 5703
2023-06-09 4 FORM 4 0001728117-23-000084 5542
2023-06-09 4 FORM 4 0001728117-23-000083 5599
2023-06-09 4 FORM 4 0001728117-23-000082 5547
2023-06-09 8-K 8-K 5.03,5.07,9.01 0001728117-23-000081 001-38796 231005421 34 571789 1 1
2023-06-09 4 FORM 4 0001728117-23-000079 5572
2023-06-09 4 FORM 4 0001728117-23-000078 5595
2023-05-10 SC 13G/A GOSSAMER_BIO_INC.txt 0000093751-23-000562 005-91334 23904608 34 8241
2023-05-09 4 FORM 4 0001728117-23-000059 31450
2023-05-09 4 FORM 4 0001728117-23-000057 31446
2023-05-09 4 FORM 4 0001728117-23-000055 22129
2023-05-09 4 FORM 4 0001728117-23-000053 26780
2023-05-09 4 FORM 4 0001728117-23-000052 5928
2023-05-09 DEFA14A DEFA14A 0001728117-23-000051 001-38796 23901860 34 32748
2023-05-09 8-K 8-K 2.02 0001728117-23-000050 001-38796 23901843 34 441273 1 1
2023-05-09 10-Q 10-Q 0001728117-23-000049 001-38796 23901798 34 5630869 1 1
2023-05-05 SC 13G/A us38341p1021_050423.txt 0001306550-23-009136 005-91334 23892238 34 12357
2023-04-28 ARS ARS 0001728117-23-000042 001-38796 23865774 34 1908391
2023-04-28 DEFA14A DEFA14A 0001728117-23-000041 001-38796 23865757 34 1907723
2023-04-28 DEF 14A DEF 14A 0001728117-23-000040 001-38796 23865732 34 3782236 1 1
2023-04-17 PRE 14A PRE 14A 0001728117-23-000034 001-38796 23823924 34 3727299 1 1
2023-04-05 4 FORM 4 0001728117-23-000032 5467
2023-04-03 8-K 8-K 8.01 0001728117-23-000030 001-38796 23792540 34 156372 1 1
2023-03-22 4 FORM 4 0001728117-23-000028 5370
2023-03-22 4 FORM 4 0001728117-23-000026 5373
2023-03-22 4 FORM 4 0001728117-23-000024 5371
2023-03-22 4 FORM 4 0001728117-23-000022 8169
2023-03-22 4 FORM 4 0001728117-23-000020 7425
2023-03-22 4 FORM 4 0001728117-23-000018 11595
2023-03-20 4 FORM 4 0001728117-23-000016 5010
2023-03-20 4 FORM 4 0001728117-23-000014 5703
2023-03-20 4 FORM 4 0001728117-23-000012 5013
2023-03-17 10-K 10-K 0001728117-23-000010 001-38796 23740695 34 10332995 1 1
2023-03-17 8-K 8-K 2.02,9.01 0001728117-23-000009 001-38796 23740692 34 228461 1 1
2023-02-14 SC 13G/A GOSSAMER BIO, INC. 0000902664-23-001807 005-91334 23629160 34 62334
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-016055 005-91334 23603397 34 12907
2023-02-01 SC 13G/A us38341p1021_020123.txt 0001306550-23-006437 005-91334 23577463 34 13197
2023-01-10 SC 13G Gossamer_Bio_Inc.txt 0000093751-23-000003 005-91334 23519693 34 10251
2023-01-04 SC 13G GOSS_SC13G_2023.htm 0001273087-23-000004 005-91334 23506743 34 81424
2022-12-20 SC 13G GOSS_SC13G.htm 0001273087-22-000123 005-91334 221475091 34 81920
2022-12-09 4 FORM 4 0001728117-22-000114 5347
2022-12-09 4 FORM 4 0001728117-22-000112 5350
2022-12-09 4 FORM 4 0001728117-22-000110 5348
2022-12-09 4 FORM 4 0001728117-22-000108 5391
2022-12-09 4 FORM 4 0001728117-22-000106 5340
2022-12-09 4 FORM 4 0001728117-22-000104 5343
2022-12-06 8-K 8-K 8.01,9.01 0001728117-22-000102 001-38796 221446706 34 5386736 1 1
2022-11-03 10-Q 10-Q 0001728117-22-000100 001-38796 221357830 34 6278550 1 1
2022-11-03 8-K 8-K 2.02 0001728117-22-000099 001-38796 221357789 34 456536 1 1
2022-10-27 4/A FORM 4/A 0001728117-22-000094 5918
2022-10-25 4 FORM 4 0001728117-22-000092 4987
2022-10-25 4 FORM 4 0001728117-22-000090 4983
2022-10-25 4 FORM 4 0001728117-22-000088 5676
2022-08-09 S-3ASR S-3ASR 0001728117-22-000086 333-266701 221148474 33 354087
2022-08-09 10-Q 10-Q 0001728117-22-000085 001-38796 221148252 34 6221561 1 1
2022-08-09 8-K 8-K 2.02 0001728117-22-000084 001-38796 221146498 34 452347 1 1
2022-07-18 D xslFormDX01/primary_doc.xml 06b 0001567619-22-014105 021-452776 221088970 33 13579
2022-07-15 4 FORM 4 0001728117-22-000078 5558
2022-07-15 4 FORM 4 0001728117-22-000076 5539
2022-07-15 4 FORM 4 0001728117-22-000073 5562
2022-07-15 4 FORM 4 0001728117-22-000071 5562
2022-07-15 4 FORM 4 0001728117-22-000069 5514
2022-07-15 4 FORM 4 0001728117-22-000067 5509
2022-07-15 4 FORM 4 0001728117-22-000065 4898
2022-07-15 4 FORM 4 0001728117-22-000063 6293
2022-07-15 4 FORM 4 0001728117-22-000061 5551
2022-07-15 4 FORM 4 0001728117-22-000059 5558
2022-07-13 8-K 8-K 1.01,3.02,7.01,9.01 0001728117-22-000057 001-38796 221080253 34 770593 1 1
2022-07-05 4 FORM 4 0001728117-22-000053 4978
2022-06-23 4 FORM 4 0001728117-22-000051 5670
2022-06-10 8-K 8-K 5.07 0001728117-22-000049 001-38796 221008858 34 39633
2022-05-10 10-Q 10-Q 0001728117-22-000047 001-38796 22909626 34 5723966 1 1
2022-05-10 8-K 8-K 2.02 0001728117-22-000046 001-38796 22909485 34 283924
2022-05-05 4 FORM 4 0001728117-22-000041 4584
2022-04-27 DEFA14A DEFA14A 0001728117-22-000039 001-38796 22860389 34 254286
2022-04-27 DEF 14A DEF 14A 0001728117-22-000038 001-38796 22860362 34 962067
2022-04-25 8-K 8-K 2.02,8.01 0001728117-22-000035 001-38796 22847383 34 35450
2022-03-24 4 FORM 4 0001728117-22-000033 6015
2022-03-24 4 FORM 4 0001728117-22-000031 5733
2022-03-24 4 FORM 4 0001728117-22-000029 5270
2022-03-17 4 FORM 4 0001728117-22-000027 4978
2022-03-17 4 FORM 4 0001728117-22-000025 4981
2022-03-17 4 FORM 4 0001728117-22-000023 5671
2022-03-03 S-8 S-8 0001728117-22-000021 333-263260 22708684 33 181674
2022-03-03 S-3ASR S-3 0001728117-22-000020 333-263259 22708629 33 871183
2022-03-03 10-K 10-K 0001728117-22-000019 001-38796 22708596 34 10110688 1 1
2022-03-03 8-K 8-K 2.02,9.01 0001728117-22-000018 001-38796 22708567 34 253819 1 1
2022-02-10 SC 13G/A SCHEDULE 13G/A 0001104659-22-017665 005-91334 22609875 34 12900
2022-02-03 SC 13G/A us38341p1021_020322.txt 0000834237-22-006295 005-91334 22589029 34 13278
2022-01-10 4 FORM 4 0001728117-22-000011 5346
2022-01-10 4 FORM 4 0001728117-22-000009 5349
2022-01-10 4 FORM 4 0001728117-22-000007 5347
2022-01-10 4 FORM 4 0001728117-22-000005 5392
2022-01-10 4 FORM 4 0001728117-22-000004 5339
2022-01-10 4 FORM 4 0001728117-22-000002 5342
2021-11-08 10-Q 10-Q 0001728117-21-000104 001-38796 211387843 34 6326713 1 1
2021-11-08 8-K 8-K 2.02,9.01 0001728117-21-000103 001-38796 211387822 34 460727 1 1
2021-10-26 4 FORM 4 0001728117-21-000100 4589
2021-10-26 4 FORM 4 0001728117-21-000098 4586
2021-10-26 4 FORM 4 0001728117-21-000096 5279
2021-10-12 8-K 8-K 7.01,8.01,9.01 0001728117-21-000094 001-38796 211317222 34 413216 1 1
2021-09-21 8-K 8-K 5.02 0001728117-21-000092 001-38796 211264929 34 399158 1 1
2021-09-20 4 FORM 4 0001728117-21-000091 5341
2021-08-09 10-Q 10-Q 0001728117-21-000087 001-38796 211156958 34 6771482 1 1
2021-08-09 8-K 8-K 2.02,9.01 0001728117-21-000086 001-38796 211156880 34 466671 1 1
2021-07-01 4 FORM 4 0001728117-21-000080 4665
2021-06-22 4 FORM 4 0001728117-21-000078 7009
2021-06-22 3 FORM 3 0001728117-21-000076 15320
2021-06-14 4 FORM 4 0001728117-21-000074 5238
2021-06-14 3 FORM 3 0001728117-21-000072 6557
2021-06-14 8-K 8-K 5.02,5.07,9.01 0001728117-21-000071 001-38796 211014857 34 428412 1 1
2021-06-10 4 FORM 4 0001728117-21-000068 5417
2021-06-10 4 FORM 4 0001728117-21-000066 5417
2021-06-10 4 FORM 4 0001728117-21-000064 5394
2021-06-10 4 FORM 4 0001728117-21-000061 5364
2021-06-10 4 FORM 4 0001728117-21-000058 5421
2021-05-06 10-Q 10-Q 0001728117-21-000056 001-38796 21897893 34 5651227 1 1
2021-05-06 8-K 8-K 2.02,9.01 0001728117-21-000054 001-38796 21895880 34 447525 1 1
2021-05-05 4 FORM 4 0001728117-21-000050 7003
2021-05-05 3 FORM 3 0001728117-21-000048 12859
2021-04-27 DEFA14A DEFA14A 0001728117-21-000045 001-38796 21859170 34 989793
2021-04-27 DEF 14A DEF 14A 0001728117-21-000044 001-38796 21859068 34 1281319
2021-04-20 4 FORM 4 0001728117-21-000040 7010
2021-04-20 3 FORM 3 0001728117-21-000038 15660
2021-04-20 8-K 8-K 5.02,9.01 0001728117-21-000037 001-38796 21838460 34 246436 1 1
2021-03-25 4 FORM 4 0001728117-21-000033 4642
2021-03-25 4 FORM 4 0001728117-21-000031 5287
2021-03-25 4 FORM 4 0001728117-21-000029 6016
2021-03-01 4 FORM 4 0001728117-21-000027 8161
2021-03-01 4 FORM 4 0001728117-21-000025 7783
2021-03-01 4 FORM 4 0001728117-21-000023 8046
2021-03-01 4 FORM 4 0001728117-21-000021 9158
2021-02-26 10-K 10-K 0001728117-21-000019 001-38796 21683852 34 9912691 1 1
2021-02-25 8-K 8-K 2.02,9.01 0001728117-21-000015 001-38796 21676465 34 262920 1 1
2021-02-16 SC 13G/A GOSSAMER BIO, INC. 0000902664-21-001418 005-91334 21638392 34 58224
2021-02-12 SC 13G SC 13G 0001728117-21-000008 37289
2021-02-12 SC 13G SC 13G 0001728117-21-000006 37442
2021-02-12 SC 13G/A SC 13G/A 0001193125-21-040874 005-91334 21625026 34 153763
2021-02-10 SC 13G/A SCHEDULE 13G/A 0001104659-21-018196 005-91334 21610878 34 13762
2021-02-02 SC 13G us38341p1021_020221.txt 0000834237-21-006835 005-91334 21580591 34 13221
2020-11-17 8-K 8-K 5.02 0001728117-20-000013 001-38796 201321994 34 192485 1 1
2020-11-10 10-Q 10-Q 0001728117-20-000009 001-38796 201301494 34 6596958 1 1
2020-11-10 8-K 8-K 2.02,9.01 0001728117-20-000008 001-38796 201301278 34 262202 1 1
2020-10-14 4 FORM 4 SUBMISSION 0001209191-20-054842 6983
2020-10-14 4 FORM 4 SUBMISSION 0001209191-20-054841 5355
2020-10-14 4 FORM 4 SUBMISSION 0001209191-20-054839 5870
2020-10-13 8-K 8-K 7.01,8.01,9.01 0001564590-20-046250 001-38796 201234616 34 8571334
2020-08-11 10-Q 10-Q 0001564590-20-039341 001-38796 201093044 34 7565090 1
2020-08-11 8-K 8-K 2.02,9.01 0001564590-20-039333 001-38796 201092850 34 185365
2020-07-02 8-K 8-K 1.01,2.03,9.01 0001564590-20-031695 001-38796 201009822 34 150880
2020-06-23 4 FORM 4 SUBMISSION 0001209191-20-038515 5874
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037679 5392
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037644 5422
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037640 5449
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037638 5445
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037635 5445
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037633 5389
2020-06-18 8-K 8-K 5.07 0001564590-20-029809 001-38796 20973219 34 49836
2020-06-09 SC 13G/A us38341p1021_060920.txt 0000834237-20-009573 005-91334 20952237 34 12302
2020-05-21 8-K 8-K 1.01,2.03,8.01,9.01 0001564590-20-026546 001-38796 20901897 34 2527989
2020-05-19 424B5 424B5 0001564590-20-026207 333-237639 20894650 33 1447679
2020-05-19 424B5 424B5 0001564590-20-026204 333-237639 20894615 33 806920
2020-05-19 FWP FWP 0001193125-20-145487 333-237639 20891536 34 51106
2020-05-18 FWP FWP 0001193125-20-145156 333-237639 20890509 34 15776
2020-05-18 305B2 305B2 0001193125-20-145062 333-237639 20889906 33 139404
2020-05-18 424B5 424B5 0001564590-20-026003 333-237639 20889713 33 1314674
2020-05-18 424B5 424B5 0001564590-20-026001 333-237639 20889634 33 749164
2020-05-12 10-Q 10-Q 0001564590-20-024690 001-38796 20869526 34 6455119 1
2020-05-12 8-K 8-K 2.02,9.01 0001564590-20-024672 001-38796 20869355 34 190582
2020-04-27 DEFA14A DEFA14A 0001564590-20-018829 001-38796 20820261 34 132087
2020-04-27 DEF 14A DEF 14A 0001564590-20-018824 001-38796 20820142 34 971189
2020-04-10 S-3ASR S-3ASR 0001564590-20-016262 333-237639 20786962 33 1114391
2020-03-24 10-K 10-K 0001564590-20-012323 001-38796 20736754 34 11406806 1
2020-03-24 8-K 8-K 2.02,9.01 0001564590-20-012321 001-38796 20736722 34 195567
2020-02-19 4 FORM 4 SUBMISSION 0001209191-20-010521 7335
2020-02-19 4 FORM 4 SUBMISSION 0001209191-20-010519 7802
2020-02-19 4 FORM 4 SUBMISSION 0001209191-20-010517 9178
2020-02-19 4 FORM 4 SUBMISSION 0001209191-20-010515 7990
2020-02-19 4 FORM 4 SUBMISSION 0001209191-20-010512 8470
2020-02-14 SC 13G GOSSAMER BIO, INC. 0000902664-20-001197 005-91334 20620667 34 60499
2020-02-14 SC 13G SC 13G 0001193125-20-037460 005-91334 20616981 34 150502
2020-02-13 SC 13G ARCH VENTURE FUND IX, L.P. - GOSSAMER BIO, INC. -- SCHEDULE 13G 0001072613-20-000101 005-91334 20611619 34 330452
2020-02-11 SC 13G SCHEDULE 13G 0001104659-20-016410 005-91334 20597435 34 13549

Latest XBRL company facts

One latest value per concept from companyfacts (304 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 6.12M 2026-11-07 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
dei EntityPublicFloat Entity Public Float USD 270.80M 2025-06-28 2025 FY 10-K 2026-03-17 0001728117-26-000017
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 3.78M 2025-01-01 2025-12-31 DEF 14A 2026-06-09 0001728117-26-000052
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.22M 2025-01-01 2025-12-31 DEF 14A 2026-06-09 0001728117-26-000052
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 9.20M 2025-01-01 2025-12-31 DEF 14A 2026-06-09 0001728117-26-000052
ecd PeoTotalCompAmt PeoTotalCompAmt USD 2.30M 2025-01-01 2025-12-31 DEF 14A 2026-06-09 0001728117-26-000052
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 143 2025-01-01 2025-12-31 DEF 14A 2026-06-09 0001728117-26-000052
ffd NetFeeAmt NetFeeAmt USD 1,560.14 2026-11-16 S-3 2026-11-16 0001728117-26-000123
ffd TtlFeeAmt TtlFeeAmt USD 1,560.14 2026-11-16 S-3 2026-11-16 0001728117-26-000123
ffd TtlOfferingAmt TtlOfferingAmt USD 17.93M 2026-11-16 S-3 2026-11-16 0001728117-26-000123
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-11-16 S-3 2026-11-16 0001728117-26-000123
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-11-16 S-3 2026-11-16 0001728117-26-000123
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 1.47M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 1.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AccruedIncomeTaxesCurrent Accrued Income Taxes, Current USD 6,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 15.87M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 1.48M 2021-09-30 2021 Q3 10-Q 2021-11-08 0001728117-21-000104
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 207,000 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -3.62M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 1.40B 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AdjustmentsToAdditionalPaidInCapitalOther Adjustments to Additional Paid in Capital, Other USD 16,000 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-17 0001728117-23-000010
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 3.79M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 10.78M 2023-01-01 2023-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 12.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AmortizationOfFinancingCostsAndDiscounts Amortization of Debt Issuance Costs and Discounts USD 6.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 8.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap Assets Assets USD 64.34M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AssetsCurrent Assets, Current USD 60.43M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 69,000 2025-12-31 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 1,000 2025-12-31 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 108.99M 2025-12-31 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year USD 298.57M 2024-09-30 2024 Q3 10-Q 2024-11-07 0001728117-24-000092
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One USD 265.52M 2024-12-31 2024 FY 10-K 2025-03-13 0001728117-25-000021
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 109.06M 2025-12-31 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 15.88M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001728117-26-000072
us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-sale, Noncurrent USD 0 2026-06-30 2026 Q2 10-Q 2026-08-13 0001728117-26-000072
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-13 0001728117-25-000021
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 51.19M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 51.19M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect USD 326.91M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-10 0001728117-20-000009
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 13.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value USD 22.20M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 2.04 2023-07-24 2024 Q1 10-Q 2024-05-07 0001728117-24-000056
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 32.47M 2023-07-24 2024 Q1 10-Q 2024-05-07 0001728117-24-000056
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 30.68M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 50.00M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 6.12M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 6.12M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap CommonStockValue Common Stock, Value, Issued USD 1,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -76.30M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ConvertibleDebtCurrent Convertible Debt, Current USD 37.15M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap CurrentFederalStateAndLocalTaxExpenseBenefit Current Federal, State and Local, Tax Expense (Benefit) USD -88,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD -94,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 6,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued shares 3.18M 2026-06-04 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 Debt Conversion, Converted Instrument, Warrants or Options Issued shares 1.88M 2026-05-18 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap DebtCurrent Debt, Current USD 11.61M 2022-09-30 2022 Q3 10-Q 2022-11-03 0001728117-22-000100
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 30.00M 2020-03-31 2020 Q1 10-Q 2020-05-12 0001564590-20-024690
us-gaap DebtInstrumentConvertibleBeneficialConversionFeature Debt Instrument, Convertible, Beneficial Conversion Feature USD 109,000 2020-04-01 2020-06-30 2020 Q2 10-Q 2020-08-11 0001564590-20-039341
us-gaap DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD 1.45M 2020-03-31 2020 Q1 10-Q 2020-05-12 0001564590-20-024690
us-gaap DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction USD 3.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions security 1 2025-12-31 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap DeferredForeignIncomeTaxExpenseBenefit Deferred Foreign Income Tax Expense (Benefit) USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 894,000 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 0 2019-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap DeferredTaxAssetsCapitalLossCarryforwards Deferred Tax Assets, Capital Loss Carryforwards USD 20.16M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 2.41M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 274.58M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 30.24M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 132.09M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 5.62M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxAssetsOtherLossCarryforwards Deferred Tax Assets, Other Loss Carryforwards USD 9.32M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 60.58M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation USD 1.98M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 11.24M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 273.69M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxLiabilitiesFinancingArrangements Deferred Tax Liabilities, Financing Arrangements USD 0 2023-12-31 2023 FY 10-K 2024-03-05 0001728117-24-000019
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 13,000 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 0 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap Depreciation Depreciation USD 13,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 5,000 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-15 0001728117-26-000032
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -17.3 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -3.55 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001728117-21-000019
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -25.61 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.124 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure -0.119 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure -0.025 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap EffectiveIncomeTaxRateReconciliationGiltiPercent EffectiveIncomeTaxRateReconciliationGiltiPercent pure -0.047 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.007 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent pure 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001728117-21-000019
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent pure 0.025 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.046 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0.014 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsOther Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent pure -0.083 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.008 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD -112,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Embedded Derivative, Fair Value of Embedded Derivative Liability USD 37.37M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet Embedded Derivative, Gain (Loss) on Embedded Derivative, Net USD 9.68M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 8.95M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 1.40M 2023-05-05 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap ExtinguishmentOfDebtGainLossNetOfTax Extinguishment of Debt, Gain (Loss), Net of Tax USD 43.85M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 54.93M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap FairValueEquityLevel1ToLevel2TransfersAmount Fair Value, Equity, Level 1 to Level 2 Transfers, Amount USD 0 2021-09-30 2021 Q3 10-Q 2021-11-08 0001728117-21-000104
us-gaap FairValueEquityLevel2ToLevel1TransfersAmount Fair Value, Equity, Level 2 to Level 1 Transfers, Amount USD 0 2021-09-30 2021 Q3 10-Q 2021-11-08 0001728117-21-000104
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap GainLossRelatedToLitigationSettlement Gain (Loss) Related to Litigation Settlement USD -2.40M 2021-10-29 2022 Q3 10-Q 2022-11-03 0001728117-22-000100
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD 43.85M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 37.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -138.05M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -170.46M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD -32.41M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest USD -243.36M 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001728117-21-000019
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD -88,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD 4.25M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -35.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 1.28M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 5,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap IncomeTaxReconciliationTaxCreditsOther Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount USD 14.23M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 1.39M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -3.13M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD -5.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -49.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap IncreaseDecreaseInEmployeeRelatedLiabilities Increase (Decrease) in Employee Related Liabilities USD -2.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap IncreaseDecreaseInInterestPayableNet Increase (Decrease) in Interest Payable, Net USD 1.05M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD 16,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -9.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap IncreaseDecreaseInReceivables Increase (Decrease) in Receivables USD -9.78M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap IncrementalCommonSharesAttributableToConversionOfDebtSecurities Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities shares 87,449 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap InterestExpense Interest Expense USD 3.13M 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-07 0001728117-24-000056
us-gaap InterestExpenseNonoperating InterestExpenseNonoperating USD 7.92M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap InterestOnConvertibleDebtNetOfTax Interest on Convertible Debt, Net of Tax USD 4.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 5.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap InterestPayableCurrent Interest Payable, Current USD 1.88M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap InterestReceivable Interest Receivable USD 0 2023-09-30 2023 Q3 10-Q 2023-11-09 0001728117-23-000134
us-gaap InterestReceivableCurrent Interest Receivable, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 1.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap InvestmentIncomeInterestAndDividend Investment Income, Interest and Dividend USD 1.58M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-17 0001728117-23-000010
us-gaap LeaseCost Lease, Cost USD 1.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate pure 0.07 2020-06-30 2020 Q2 10-Q 2020-08-11 0001564590-20-039341
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 4.44M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 397,000 2020-12-31 2020 FY 10-K 2021-02-26 0001728117-21-000019
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 1.41M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 1.24M 2024-12-31 2024 FY 10-K 2025-03-13 0001728117-25-000021
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 1.24M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 1.24M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 1.45M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 349,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 740,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap Liabilities Liabilities USD 187.13M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 64.34M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap LiabilitiesCurrent Liabilities, Current USD 99.94M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap LitigationReserveCurrent Estimated Litigation Liability, Current USD 0 2022-12-31 2022 FY 10-K 2023-03-17 0001728117-23-000010
us-gaap LongTermDebt Long-term Debt USD 28.55M 2020-03-31 2020 Q1 10-Q 2020-05-12 0001564590-20-024690
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 0 2024-12-31 2024 FY 10-K 2025-03-13 0001728117-25-000021
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive Long-Term Debt, Maturity, after Year Five USD 4.17M 2019-09-30 2019 Q3 10-Q 2019-11-12 0001564590-19-042943
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 0 2019-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive Long-Term Debt, Maturity, Year Five USD 4.17M 2020-03-31 2020 Q1 10-Q 2020-05-12 0001564590-20-024690
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four USD 10.00M 2020-03-31 2020 Q1 10-Q 2020-05-12 0001564590-20-024690
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 10.00M 2020-03-31 2020 Q1 10-Q 2020-05-12 0001564590-20-024690
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 5.83M 2020-03-31 2020 Q1 10-Q 2020-05-12 0001564590-20-024690
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Long-Term Debt, Maturity, Remainder of Fiscal Year USD 0 2020-09-30 2020 Q3 10-Q 2020-11-10 0001728117-20-000009
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 0 2024-12-31 2024 FY 10-K 2025-03-13 0001728117-25-000021
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 21.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 100.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -107.72M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -77.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -77.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD -117.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD -14.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap NotesIssued1 Notes Issued USD 18.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap NumberOfOperatingSegments Number of Operating Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap NumberOfReportableSegments Number of Reportable Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OperatingExpenses Operating Expenses USD 128.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -63.74M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OperatingLeaseCost Operating Lease, Cost USD 1.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 2.80M 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-07 0001728117-24-000092
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 3.70M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 1.01M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 2.69M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OperatingLeasePayments Operating Lease, Payments USD 1.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 3.44M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 697,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 15.75M 2018-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 2.94M 2018-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 1.69M 2018-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 3.22M 2018-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 3.12M 2018-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 3.04M 2018-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 1.74M 2018-12-31 2019 FY 10-K 2020-03-24 0001564590-20-012323
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 1.50M 2018-01-01 2018-12-31 2020 FY 10-K 2021-02-26 0001728117-21-000019
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.124 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 765,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 424,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax USD 1.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD 1.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -68,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -5.79M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 1.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 200,000 2022-07-15 2024 FY 10-K 2025-03-13 0001728117-25-000021
us-gaap PaymentsToAcquireInvestments Payments to Acquire Investments USD 399.39M 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-12 0001564590-19-042943
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 24.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2021-09-30 2021 Q3 10-Q 2021-11-08 0001728117-21-000104
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 70.00M 2021-09-30 2021 Q3 10-Q 2021-11-08 0001728117-21-000104
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2021-09-30 2021 Q3 10-Q 2021-11-08 0001728117-21-000104
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2021-09-30 2021 Q3 10-Q 2021-11-08 0001728117-21-000104
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2021-09-30 2021 Q3 10-Q 2021-11-08 0001728117-21-000104
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 9.24M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ProceedsFromConvertibleDebt Proceeds from Convertible Debt USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-17 0001728117-23-000010
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 117.10M 2020-05-21 2024 FY 10-K 2025-03-13 0001728117-25-000021
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 73.49M 2018-01-01 2018-06-30 2019 Q2 10-Q 2019-08-08 0001564590-19-030814
us-gaap ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt USD 28.22M 2019-01-01 2019-06-30 2020 Q2 10-Q 2020-08-11 0001564590-20-039341
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 23.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap ProceedsFromLongTermLinesOfCredit Proceeds from Long-term Lines of Credit USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-03 0001728117-22-000019
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 205.75M 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-12 0001564590-19-042943
us-gaap ProceedsFromSaleMaturityAndCollectionsOfInvestments Proceeds from Sale, Maturity and Collection of Investments USD 25.50M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-14 0001564590-19-018973
us-gaap ProceedsFromSaleOfInvestmentProjects Proceeds from Sale of Investment Projects USD 4.00M 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-12 0001564590-19-042943
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 220,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 358,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -77.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 271,000 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 51,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap RealizedInvestmentGainsLosses Realized Investment Gains (Losses) USD 5,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap RepaymentsOfLongTermDebt Repayments of Long-term Debt USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap RepaymentsOfRelatedPartyDebt Repayments of Related Party Debt USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001728117-21-000019
us-gaap ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff Research and Development Asset Acquired Other than Through Business Combination, Written-off USD 30,000 2023-01-01 2023-06-30 2023 Q2 10-Q 2023-08-08 0001728117-23-000108
us-gaap ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Research and Development Expense (Excluding Acquired in Process Cost) USD 88.31M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 15,000 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-09 0001728117-23-000049
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 0 2022-12-31 2022 FY 10-K 2023-03-17 0001728117-23-000010
us-gaap RestructuringAndRelatedCostExpectedCost1 Restructuring and Related Cost, Expected Cost USD 6.10M 2026-03-16 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminated Restructuring and Related Cost, Number of Positions Eliminated individual 73 2026-03-16 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.46 2026-03-16 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.52B 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 64.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 13.25 2020-05-21 2024 FY 10-K 2025-03-13 0001728117-25-000021
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 12.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value USD/shares 9.62 2022-06-30 2022 Q2 10-Q 2022-08-09 0001728117-22-000085
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-05 0001728117-24-000019
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 300,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 709,008 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 136.81 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 1.77M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 77,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 1.65M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 34.16 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number shares 369,907 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price USD/shares 82.59 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 77,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 1.65M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 34.16 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 100,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value USD/shares 35.11 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Share-based Payment Arrangement, Plan Modification, Incremental Cost USD 3.40M 2023-05-05 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 83.04 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 40.31 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding shares 6.82M 2023-05-05 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price USD/shares 1.36 2023-05-05 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap SharePrice Share Price USD/shares 239.2 2025-09-24 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares shares 0 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 17,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD -122.80M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.013 2026-09-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap StockIssued1 Stock Issued USD 45.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Stock Issued During Period, Shares, Conversion of Convertible Securities shares 254.15M 2026-04-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001728117-26-000072
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 9.43M 2020-05-21 2024 FY 10-K 2025-03-13 0001728117-25-000021
us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures shares 485,439 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-03 0001728117-22-000019
us-gaap StockIssuedDuringPeriodSharesShareBasedCompensationForfeited Shares Issued, Shares, Share-based Payment Arrangement, Forfeited shares 0 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-09 0001728117-23-000134
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 2,628 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap StockIssuedDuringPeriodValueAcquisitions Stock Issued During Period, Value, Acquisitions USD 2.88M 2018-01-01 2018-12-31 2020 FY 10-K 2021-02-26 0001728117-21-000019
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 47.80M 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 66,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 201.32M 2023-01-01 2023-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap StockIssuedDuringPeriodValuePurchaseOfAssets Stock Issued During Period, Value, Purchase of Assets USD 7.48M 2025-07-01 2025-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures USD 0 2021-04-01 2021-06-30 2021 Q3 10-Q 2021-11-08 0001728117-21-000104
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 220,000 2026-01-01 2026-03-31 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares shares 3.43M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-10 0001728117-20-000009
us-gaap SubleaseIncome Sublease Income USD 0 2020-01-01 2020-06-30 2021 Q2 10-Q 2021-08-09 0001728117-21-000087
us-gaap TemporaryEquityStockIssuedDuringPeriodValueNewIssues Temporary Equity, Stock Issued During Period, Value, New Issues USD 0 2018-07-01 2018-09-30 2019 Q3 10-Q 2019-11-12 0001564590-19-042943
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 15.46M 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 1.36M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 2.90M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 45.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001728117-26-000017
us-gaap VariableLeaseCost Variable Lease, Cost USD 1.13M 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-12 0001564590-19-042943
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 4.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 68.51M 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001728117-21-000019
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 4.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001728117-26-000114

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →